Hamlet BioPharma Investigates Tumor Treatment Derived from Human Milk

Hamlet BioPharma is developing a new cancer therapy focused on HAMLET, a protein complex derived from human milk. The company reports that HAMLET has the ability to destroy a wide range of cancer cells while leaving healthy cells unharmed, distinguishing it from many conventional cancer drugs.

Research has indicated HAMLET's efficacy against numerous cancer types. Clinical trials have shown topical administration of HAMLET to remove skin papillomas without adverse effects. In bladder cancer patients, HAMLET has reportedly induced rapid shedding of tumor cells into urine and reduced tumor size. The company suggests that cancer cell sensitivity to HAMLET is linked to oncogene profiles, particularly c-Myc expression levels, and the tumor's metabolic state.

A key advantage of HAMLET is its natural, non-toxic mechanism of action, contrasting with many current cancer drugs that can damage healthy tissues. Hamlet BioPharma hypothesizes that HAMLET's presence in human milk may contribute to lower cancer incidence in breastfed infants and mothers.

The company aims to further develop HAMLET into a new therapeutic concept by integrating studies on its structure and mechanism of action with preclinical and clinical efficacy studies across various cancer models.